Literature DB >> 3114186

The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy.

M Catterall, R D Errington.   

Abstract

The conventional treatment for cancer of the salivary glands is surgery, with or without X ray therapy. In advanced tumors (Stage III and IV), local control and 5-year survival rates are less than 35%. Radical surgery severs the facial nerve in the majority of operations on parotid gland tumors. Local control of unresectable salivary gland tumors was achieved, in 74% of cases, by fast neutron therapy. From the MRC cyclotron at Hammersmith Hospital neutrons were given to 65 patients, with locally advanced or recurrent tumors, 89% of which were Stage IV. Local control and 5-year survival rates were 72% and 50%, respectively. The facial nerve was not damaged by neutron therapy. In patients with parotid gland tumors, 77% regained or maintained function. Function was lost in 14% through recurrence and 9% remained paralyzed. The results were achieved using beams from primitive machines with serious disadvantages. The results from neutrons implicate improvements for locally advanced tumors of non-epidermal origin in other sites of the body, especially with the high energy neutrons now available from modern cyclotrons.

Entities:  

Mesh:

Year:  1987        PMID: 3114186     DOI: 10.1016/0360-3016(87)90222-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Results of fast neutron therapy of adenoid cystic carcinoma of the salivary glands.

Authors:  R Pötter; F J Prott; O Micke; U Haverkamp; W Wagner; N Willich
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

Review 2.  [Salivary gland carcinomas Part II. Diagnosis and therapy].

Authors:  S Lang; N Rotter; A Lorenzen; S Ihrler; R Eckel; D Hölzel; G Rasp; B Wollenberg; K Sommer
Journal:  HNO       Date:  2005-10       Impact factor: 1.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.